Every Immune Tolerance Network (ITN) trial integrates a set of genetic, cellular and immunological studies that are designed to explore the underlying mechanisms of tolerance and disease. They help to identify new clinical phenotypes by stratifying individuals in the clinical trials, and to discover new biomarkers that may illuminate drug targets or be useful for personalizing therapy. To accomplish this, the ITN has developed the following core laboratories and facilities that utilize state-of-the-art and custom-made assays.
Distributed Centers of Excellence
Allergy & Asthma
Principle Investigators: Professor Stephen Durham and Dr. Mohamed Shamji | Imperial College, London, UK
Principle Investigator: Professor Allan Kirk | Duke University, Durham, NC
Principle Investigators: Dr. Jane Buckner and Dr. Alice Long | Benaroya Research Institute, Seattle, WA